1. Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review
   Jared Becerril-Rico et al, 2023, Leukemia & Lymphoma CrossRef
2. Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
   Songmi Wang et al, 2023, Frontiers in Pediatrics CrossRef
3. Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy
   Yu Zhao et al, 2022, Frontiers in Oncology CrossRef
4. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review
   Franco Locatelli et al, 2023, Leukemia & Lymphoma CrossRef
5. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
   Wei Chen et al, 2021, Frontiers in Immunology CrossRef